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1. Introduction  
The steroidal and non-steroidal anti-inflammatory drugs are known to be among the most 
commercialized drugs worldwide, however several discussions have been raised about its 
side effects, caused especially in the chronic use. In this context, the discovery of new 
prototypes with improved anti-inflammatory activity and therapeutic safety is one of the 
targets in the area of research, development and innovation of the pharmaceutical industry. 
The intensive search for new anti-inflammatory therapeutic options with effective therapies 
and fewer adverse effects resulted in the development of non-steroidal anti-inflammatory 
drugs (NSAIDs) with selective inhibition of cyclooxygenase-2 (coxibs). This new generation 
of drugs came to market due to their greater efficiency and minor capacity to damage gastric 
and renal sites compared to non-selective NSAIDs. This advantage would be 
pharmacodynamically explained by its ability to selectively inactivate the inducible 
cyclooxygenase-2 (COX-2), the enzyme that induces prostaglandin synthesis at the 
inflammation site, preserving the constitutive cyclooxygenase-1 (COX-1) responsible for 
physiological protection carried by prostaglandins in those sites. Despite the therapeutic 
efficiency, some of the developed coxibs has been removed from the market by causing 
significant cardiovascular effects.  
Thus, efforts are still underway to discover new anti-inflammatory chemical entities. Several 
studies have been conducted with synthetic agonists (thiazolidinodiones) of a biological 
anti-inflammatory target discovered in the nineties, the peroxisome proliferator activated 
receptor Ǆ (PPARǄ). The research of drugs with anti-inflammatory activity carried out by 
different mechanisms of action from the conventional ones is extremely important in an 
attempt to expand the therapeutic options for patients who have restrictions on the use of 
the available anti-inflammatory drugs. 
1.1 History 
The hability to treat fever and inflammation dates back to 2500 years ago (400 B.C.) to a time 
when the Greek physician Hippocrates prescribed an extract from willow bark and leaves 
(Rao & Knaus, 2008). Later, in 1860, with the discovery of the active ingredient of willow 
bark salicin in Europe, the Kolbe company in Germany started mass producing salicylic 
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acid. Acetysalicylic acid (Aspirin®), the more palatable form of salicylic acid was introduced 
into the market by Bayer in 1899 (Vane, 2000). 
In the 1930s and 1940s, numerous developed studies allowed the recognition of the effects of 
adrenocortical hormones on electrolyte balance (mineralocorticoids effects) and 
carbohydrate metabolism (glucocorticoids effects). In 1946, cortisol was synthesized, and in 
1948, first used by Hench in patients with rheumatoid arthritis. In the 1950s, changes in the 
structure of cortisol resulted in new drugs such as prednisone and prednisolone. Later, the 
side effects related to the use of these therapies have been recognized, adding limitations to 
the therapeutic use of glucocorticosteroids.  
In 1946 was brought to the market phenylbutazone, the first drug other than Aspirin® of the 
category of what are now known as the NSAIDs, followed by indomethacin in the 1960’s (by 
Merck & Co). In the 1950-1960’s Ibuprofen was developed by Boots (UK), and it was the first 
NSAID (other than Aspirin®) to be approved for non-prescription use in the UK (1963), then 
USA (1964), and later in many other countries worldwide. Just after the advent of Ibuprofen, 
in the seventies John Vane discovered the mechanism of action of Aspirin® and other 
NSAIDs: the inhibition of cyclooxygenase (COX) enzyme (Vane, 1971). After that, a large 
number of pharmaceutical companies undertook the discovery and development of many 
other NSAIDs. 
In the early 90’s there was reported the presence of an inducible isoform of the COX 
enzyme, later identified as COX-2 (Kujubu & Herschman, 1992). This discovery led to the 
hipothesis that the non-inflammatory prostaglandins were produced by the constitutive 
COX-1 and pro-inflammatory prostaglandins by the non-constitutive COX-2 (Meade et al., 
1993). The conventional anti-inflammatory drugs were known to inhibit both isoforms of the 
enzyme. The COX-1 inhibition would explain the gastrointestinal adverse effects caused by 
the NSAIDs. In an attempt to research new therapeutic agents with fewer adverse effects, 
the pharmaceutical companies focused their efforts on the design of selective COX-2 
inhibitors. In 1999, G.D. Searle and Pfizer (now Pfizer Inc) launched the first selective COX-2 
inhibitor, celecoxib (Celebrex®) (Rao & Knaus, 2008). This was followed by the launch of 
Merck’s rofecoxib (Vioxx®) and other coxibs (Prasit, 1999).  
The research and development of new therapies to treat inflammation, pain and arthritis is 
still a constant in the pharmaceutical industry. Between 1999 and 2010, at least 12 arthritis 
and inflammation related new chemical and biological entities were released, 5 of them anti-
inflammatory agents. However, rofecoxib (Vioxx®) and valdecoxib (Bextra®) were still 
withdrawn from the market due to the high cardiovascular risk related to its use (United 
States Food and Drug Administration [FDA], 2011). 
1.2 Anti-Inflammatory use and market 
The anti-inflammatory class of drugs is among the most widely prescribed groups of 
medicines in clinical practice worldwide. The global market for treatment of pain in 2009 
amounted to US$ 50 billion, of which 27 billion in the seven largest economies (USA, Japan, 
France, Germany, Italy, Spain and UK). Of these US$ 27 billion, NSAIDs constitute 28% 
NSAIDs and selective COX-2 inhibitors 7% (Melnikova, 2010). Other data that brings the 
high use of anti-inflammatory drugs reveal that 40 thousand tons of acetyl-salicylic acid are 
ingested every year around the world (Menezes et al., 2009), besides the large number of 
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NSAIDs available for purchase in the market, many of them obtained without prescription. 
This fact can explain the high cash income derived from the NSAIDs prescription. 
Recently, a study carried out in six European countries showed an increase in the use of 
anti-inflammatory drugs during the 2002-2007 period. It is important to emphasize that 
during this period the use of conventional NSAIDs increased by 2.07%, while the stronger 
COX-2 inhibitors use increased by 325% (Inotai et al., 2010). 
The numbers regarding the use of corticosteroids as anti-inflammatory therapy in the U.S. 
shows that each year approximately 67 million prescriptions are written, despite their 
multiple side effects. In 2007, the combined annual sales for corticosteroids totaled about 
US$ 7.4 billion, not including generics (Hollis-Eden Pharmaceuticals, 2007). 
Associated with these high values regarding anti-inflammatory therapies, there are other 
ones related to its adverse effects. Some studies developed at the US showed that, for each 
dollar spent on NSAIDs, from U$0.66 to U$1.25 may be spent due to gastrointestinal adverse 
effects. Aditionally, almost 1/3 of the medical costs in arthritis patients may be related with 
gastrointestinal effects (Laine et al., 2010). 
1.3 Physiopathology 
Acute inflammation may be triggered by a variety of stimuli and is characterized by the 
rapid host response to the sites of infection or tissue injury, with the delivery of leukocytes 
and plasma proteins, such as antibodies, to the referred site. Chronic inflammation may 
develop following acute inflammation and may last for weeks or months, and in some 
instances for years.  
During both acute and chronic inflammatory processes, a number of soluble factors are 
involved in leukocyte recruitment through increased expression of cellular adhesion 
molecules and chemoattraction. Through this mechanism, many soluble mediators regulate 
the activation of resident cells, such as endothelial cells, fibroblasts, tissue macrophages and 
mast cells, as well as newly recruited inflammatory cells such as monocytes, lymphocytes, 
neutrophils and eosinophils. Some of these mediators result in the systemic inflammatory 
responses, as fever, hypotension, the synthesis of acute phase proteins, leukocytosis and 
cachexia (Feghali & Wright, 1997). 
Some transcription factors play a significant role in the inflammatory process. In this 
context, an important one is Nuclear Factor-kappa B (NF-κB), which controls the 
transcription of DNA (Gilmore, 2006). Activation of the NF-κB transcription family, by 
nuclear translocation of cytoplasmic complexes, plays a central role in inflammation 
through its ability to induce transcription of proinflammatory genes and consequently 
mediators like cytokines and chemokines, matrix metalloproteinases (MMPs), COX-2, and 
inducible nitric oxide (iNOS) (Baldwin, 1996). NF-κB activation also increases expression of 
the adhesion molecules E-selectin, vascular cell adhesion molecule 1 (VCAM-1), and 
intercellular adhesion molecule 1 (ICAM-1), while inhibition reduces leukocyte adhesion 
and transmigration (Chen et al., 1995). The activity of NF-kB is tightly regulated by 
interaction with inhibitory IkB proteins (Gilmore, 2006). 
The mediators that act in the inflammatory process can be divided in cell-derived and 
plasma protein-derived. These include: 
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 Cell-derived: Histamin, Serotonin, Prostaglandins, Leukotrienes, Platelet-activating 
factor, Reactive oxygen species, Nitric oxide, Cytokines (tumor necrosis factor – TNF, 
interleukin-1 – IL-1), Chemokines; 
 Plasma-protein derived: Complement products (C3a, C4a, C5a), Kinins, Proteases 
activated during coagulation. 
Among the mediators of inflammation many are derived from the arachidonic acid. The 
scheme below shows the biochemical cascade that leads to some of them (Figure 1): 
Phospholipid
Arachidonic
acid
Lyso-glyceryl-
phosphorylcholine
12-HETE
(chemotaxin)
PGG2 5-HPETE
PGH2
LTA4
PGE2 PGF2a
TXA2
PGD2
PGI2
LTB4 LTC4
LTD4
LTE4
12-Lipoxygenase 12-Lipoxygenase 5-LipoxygenaseCyclo-oxygenase
Phospholipase A2
PAF
PG antagonists
Leucotriene
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(induce lipocortin)
5-Lipoxygenase
inhibitors
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Glucocorticoids
inhibit induction
Lipoxins
A and B
 
Fig. 1. The arachidonic acid cascade leads to a number of mediators of inflammation. As 
indicated in red, many steps of this cascade are potential anti-inflammatory targets, such as 
enzymes and eicosanoids receptors. In this chapter, will be discussed the NSAIDs and 
glucocorticosteroids. PAF, platelet-activating factor; PG, prostaglandin; 12-HETE, 12-
hydroxyeicosatetraenoate; 5-HPETE, 5-hydroperoxyeicosatetraenoate; TXA2, thromboxane 
A2; LT, leukotriene.  
The classic anti-inflammatory therapies are based on the inhibition of the cyclooxygenase 
enzymes (NSAIDs) and cyclooxygenase 2 expression (glucocorticosteroids), thus preventing 
the prostanoids to be generated and on the phospholipase A2 enzyme expression inhibition 
(glucocorticosteroids), inhibiting the whole arachidonic acid cascade. Moreover, 
corticosteroids induce key anti-inflammatory genes and selectively repress specific 
inflammatory genes that encode a number of other mediators of inflammation, consequently 
inhibiting the inflammatory response. The anti-inflammatory response of these medicines can 
be explained by the reduction of the inflammatory response of such mediators, once its 
generation is decreased by the action of the medicines. Many side effects experienced by these 
drugs users can be explained by the absent physiological role of these mediators (Table 1).  
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PGI2 PGD2 & PGF2 PGE2 TXA2 
Platelets: Inhibits 
platelet aggregation 
and disaggregates 
preformed clumps. 
Limits platelet 
activation by TxA2, 
reducing the 
thrombotic response 
to vascular injury. 
Kidneys: Maintain 
renal blood flow and 
salt excretion. PGI2 
promotes renin release 
and natriuresis via 
effects on tubular 
reabsorption of Na+. 
Vascular smooth 
muscle (PGF2): 
Vasoconstriction; 
Uterus: Relaxation 
(PGD2) and 
contraction (PGF2). 
Pregnancy: COX-2-derived PGE2 
maintains the ductus arteriosus patent 
until birth. Reduced PGE2 levels permit 
closure. Stimulates contraction of the 
pregnant human uterus; 
Kidneys: Maintain renal blood flow 
and salt excretion; 
Gastric and intestinal secretions: 
Contributes to increased mucus 
secretion (cytoprotection), inhibition of 
gastric acid secretion, and reduced 
pepsin content. Inhibits gastric damage 
caused by a variety of ulcerogenic 
agents and promote healing of 
duodenal and gastric ulcers; 
Bones: Stimulates bone formation by 
increasing osteoblastogenesis. Bone 
resorption also is mediated via PGE2, 
through activation of osteoclasts 
Platelets: 
Induces platelet 
aggregation; 
Vascular tone: 
Causes 
vasoconstriction; 
Parturition: 
Important in the 
final stages of 
parturition. 
Inflammation: 
Increases local blood 
flow, vascular 
permeability, and 
leukocyte infiltration 
Pain: Reduces the 
threshold to 
stimulation of 
nociceptors, causing 
peripheral sensitization. 
Inflammation 
(PGD2): Contributes 
to inflammation in 
allergic responses. 
Increases perfusion 
and vascular 
permeability and 
promotes TH2 cell 
differentiation. PGD2 
also can activate 
mature TH2 cells and 
eosinophils via its 
DP2 receptor. 
Inflammation: Increases local blood 
flow, vascular permeability, and 
leukocyte infiltration 
Pain: Reduces the threshold to 
stimulation of nociceptors, causing 
peripheral sensitization 
Fever: PGE2 can cross the blood-brain 
barrier and acts on EP3 and perhaps 
EP1 receptors on thermosensitive 
neurons. This triggers the 
hypothalamus to elevate body 
temperature by promoting an increase 
in heat generation and a decrease in 
heat loss. 
Inflammation: 
Increases 
platelet–
leukocyte 
interaction. 
Table 1. The diverse activities of prostaglandins are reflected by their involvement in both 
normal homeostasis (blue) and pathophysiology (red). Many of the NSAIDs side effects can 
be explained by the absent physiological role of prostanoids (renal, cardiovascular, 
gastrointestinal) due to the COX inhibition (Goodman et al., 2010). 
Among the soluble factors that mediate inflammation, a group of secreted polypeptides 
known as cytokines play essential roles in orchestrating the process. They can be divided 
into two groups: those involved in acute inflammation and those responsible for chronic 
inflammation (See Figure 2 and Table 2). 
The most important cytokines involved in inflammatory reactions are listed. In this context, 
TNF-ǂ and IL-1 are important in developing the acute and sustaining the chronic 
inflammatory process (O’Neill, 2008). Working in concert with each other and various 
cytokines and growth factors (such as IL-6, IL-8 and granulocyte-macrophage colony-
stimulating factor [GM-CSF]), they induce gene expression and protein synthesis (including 
expression of COX-2, adhesion molecules, and acute-phase proteins) in a range of cells to 
mediate and promote inflammation. Other cytokines may play lesser roles in inflammation.  
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ACUTE INFLAMMATION
IL-8
IL-16
G-CSF
IL-1
IL-6
IL-11
TNF-
Eotaxin
GM-CSF
IL-2
IL-4
IL-7
IL-10
IL-13
IL-15
TGF-
TNF-
IL-3
IL-5
IL-9
IL-12
IL-14
IL-17
IFNs
CHRONIC INFLAMMATION  
Fig. 2. Cytokines involved in acute and chronic inflammatory responses. IL, interleukin; 
TNF, tumor necrosis factor; GM-CSF, Granulocyte-colony stimulating factor; TGF, 
Transforming growth factor; IFN, interferon. 
Principal 
cytokines 
Principal sources Principal actions in inflammation 
TNF 
Mast Cells, Macrophages, T 
lymphocytes 
Stimulates expression of endothelial 
adhesion molecules and secretion of other 
cytokines; systemic effects 
IL-1 Macrophages, endothelial cells Similar to TNF; greater role in fever 
IL-6 Macrophages, other cells Systemic effects 
IL-12 Dendritic cells, macrophages Increased production of IFN-Ǆ 
IL-17 T-Lymphocytes Recruitment of neutrophils and monocytes 
Chemokines 
Macrophages, endothelial cells, T 
lymphocytes, mast cells, other cell 
types 
Recruitment of leukocytes to sites of 
inflammation; migration of cells to normal 
tissues 
IFN-Ǆ T lymphocytes, NK cells Activation of macrophages (increased 
ability to kill microbes and tumor cells) 
Table 2. Principal cytokines in inflammation (Robbins et al., 2010). NK, natural killer. 
The extravasion of leukocytes is controlled by the expression of cell surface adhesion 
molecules on both the circulating cells and on the vascular endothelium. The TNF-ǂ 
signaling pathway, mediated by NF-κB, is responsible for the expression of adhesion 
molecules such as VCAM-1 and ICAM-1 in the endothelium (Collins et al., 1995). TNF-ǂ 
was previously shown to induce ICAM-1 expression (Fingar et al., 1997). These adhesion 
molecules allow the attachment of leukocytes to the endothelium and may permit their 
subsequent transmigration into peripheral tissue. At the same time, microvascular 
permeability is increased (Frank & Lisanti, 2008). 
2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
The NSAIDs are a heterogeneous group of molecules that share certain therapeutic actions 
and side effects. The first drug belonging this class, Aspirin®, was introduced to the market 
in 1899. After that, several other anti-inflammatory drugs were introduced over the years, 
until the discovery of selective inhibitors of COX-2, called coxibs. Both traditional NSAIDs 
and the recent coxibs are effective anti-inflammatory agents and analgesics. However, in 
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recent years it has been questioned the safety associated with the use of these drugs in 
clinical practice, due to the range of side effects caused due to consumption of these drugs, 
many times inappropriately. 
2.1 Mechanism of action 
The anti-inflammatory action of NSAIDs can be explained by the effect of inhibiting the 
enzyme COX, which is responsible for the synthesis of prostaglandins, mediators with a 
great ability to induce inflammation (Tanaka et al., 2009). COX has two isoforms: COX-1 and 
COX-2. The first is constitutively expressed in a wide variety of cells, promoting 
physiological functions, such as gastric mucosal protection, control of renal blood flow, 
hemostasis, autoimmune responses, lungs, central nervous system, cardiovascular system 
and reproductive functions (Grosser et al., 2006). 
On the other hand, COX-2 is an inductive enzyme, which is expressed significantly due to 
various stimuli such as cytokines, endotoxins and growth factors. COX-2 originates 
inducing prostaglandins, which contribute to the development of the four cardinal signs of 
inflammation: pain, heat, redness and swelling (Fitzgerald, 2004), thus being considered as 
the main target for the anti-inflammatory action. In this context, the recently developed 
coxibs act through selective inhibition of COX-2. However, although inductive, this COX 
isoform is also expressed in normal vascular endothelial cells, synthesizing prostacyclin, an 
important substance in maintaining the prothrombotic/antithrombotic blood balance 
(Antman et al., 2007), which can trigger severe cardio-vascular problems. 
2.2 Therapeutic uses 
The effects of inhibiting the COX enzyme explain the clinical uses of the NSAIDs (including 
selective COX-2 inhibitors), mainly as antipyretics, analgesics and anti-inflammatory agents. 
 Inflammation: As anti-inflammatory agents, are used to treat muscle injuries, 
tendinitis, bursitis and in relieving postoperative pain, in addition to its indication for 
chronic rheumatic diseases such as rheumatoid arthritis, osteoarthritis, gouty arthritis 
and ankylosing spondylitis (Pountos et al., 2011). In the latter cases, NSAIDs are often 
associated with disease modifying anti-rheumatic drugs (DMARDs), so that in addition 
to reducing pain and discomfort of the patient, also promote the regression of the 
disease.  
 Pain: Its use as analgesic is indicated for relieving mild to moderate pain. They are 
particularly effective when inflammation has caused peripheral and/or central 
sensitization of pain perception. Thus, postoperative pain or pain arising from 
inflammation, such as arthritic pain, is controlled well by NSAIDs, whereas pain arising 
from the hollow viscera usually is not relieved (Goodman et al., 2010). 
 Fever: NSAIDs are thought to be antipyretic largely through inhibition of prostaglandin 
production in the hypothalamus. They can reduce fever in most situations, but not the 
circadian variation in temperature or the rise in response to exercise or increased 
ambient temperature. McAdam et al. (1999), in a comparative study of the impact of 
non-selective NSAIDs and selective COX-2 inhibitors, suggested that COX-2 is the main 
source of PGs that mediate the rise in temperature caused by bacterial 
lipopolysaccharide (LPS) administration. 
www.intechopen.com
 
Pharmacotherapy 
 
122 
 Cardioprotection: The suppression of platelet TxA2 formation promotes the 
cardioprotective effect of aspirin. It is used as an antiplatelet drug, in the management 
of the myocardial infarction and in angina, reducing the risk of serious vascular events 
in high-risk patients (e.g., those with previous myocardial infarction) by 20-25%. Low-
dose (<100 mg/day) aspirin, is as effective as higher doses (e.g., 325 mg/day) but is 
associated with a lower risk for gastrointestinal adverse events (Goodman et al., 2010). 
 Cancer Chemoprevention: Studies of patients with familial adenomatous polyposis and 
Gardner’s syndrome (Waddell et al., 1983, 1989) introduced the idea that NSAIDs may 
inhibit cancer progression. Cha & Raymond (2007) found that in colorectal cancers the 
same occurs because COX-2 is selectively upregulated, which was subsequently found to 
be elevated in other epithelial tumors including breast, stomach, pancreas, bladder, lung 
and prostate cancers. Since the NSAID action is inhibition of the enzymatic activities of 
COX-1 and COX-2, it was hypothesized that the beneficial effect of NSAIDs was due, in 
part, to inhibition of COX-2 in the tumor microenvironment. Additionally, recent clinical 
trials clearly demonstrate that celecoxib is very effective in reducing polyp recurrence in 
patients who have undergone a polypectomy (Arber et al.; Bertagnolli et al., 2006). This 
drug is particularly effective in reducing recurrence of very large polyps, which are more 
likely to progress into cancer. Recently, a new group of NSAIDs have been explored for 
their effectiveness in several diseases, such as cardiovascular, rheumatological and lung 
diseases, Alzheimer's disease, and cancer: the Nitric oxide-donating nonsteroidal 
antiinflammatory drugs (NO-NSAIDs). These drugs consist of a traditional NSAID to 
which a NO releasing moiety is covalently attached, and may have an important role in 
colon cancer prevention and/or treatment (Yeh et al., 2004).  
 Alzheimer's Disease: Observational studies have suggested that NSAID use, in 
particular ibuprofen, is associated with lower risk of developing Alzheimer's disease. 
The same was not observed when a randomized, controlled clinical trial comparing 
celecoxib, naproxen, and placebo (ADAPT Research Group, 2008) was performed, 
where the researchers did not find a significant reduction in Alzheimer's dementia with 
the use of NSAIDs. 
 Other Clinical Uses: In patients with systemic mastocytosis, PGD2, released from mast 
cells in large amounts, has been found to be the major mediator of severe episodes of 
flushing, vasodilation, and hypotension. The addition of aspirin or ketoprofen has 
provided relief (Worobec, 2000). Large doses of niacin (nicotinic acid), effectively used to 
lower serum cholesterol levels, reduce low-density lipoprotein, and raise high-density 
lipoprotein, can induce intense facial flushing. This flushing is mediated largely by release 
of PGD2 from the skin, which can be inhibited by treatment with aspirin (Jungnickel et al., 
1997). Bartter syndrome includes a series of rare disorders characterized by hypokalemic, 
hypochloremic metabolic alkalosis with normal blood pressure and hyperplasia of the 
juxtaglomerular apparatus. Renal COX-2 is induced, and biosynthesis of PGE2 is 
increased. Treatment with indomethacin, combined with potassium repletion and 
spironolactone, is associated with improvement in the biochemical derangements and 
symptoms. Selective COX-2 inhibitors also have been used (Guay-Woodford, 1998). 
2.3 Side effects 
The use of NSAIDs has been associated with a high number of side effects. Thus, the 
prescription of these drugs should be made through a previous study of the individual patient, 
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taking into account the required dosage and the use of other drugs, in order to understand the 
patient risk-benefit relation. The most prominent side effects are described below: 
 Gastrointestinal effects: Several prostanoids, especially prostacyclin and PGE 2, are 
crucial to protect the gastric mucosa from the corrosive effects of stomach acid, as well 
as to maintain the naturally healthy condition of the gastric mucosa (Antman, 2007). 
Therefore, the consequences of inhibition of COX-1 may lead to the triggering of 
various side effects ranging from nausea to bleeding ulcers, which can lead the user to 
death (Pountus et al., 2011). The use of high doses or the prolonged consumption of 
NSAIDs, along with its administration with corticosteroids and/or anticoagulant drugs, 
smoking and/or alcohol, increases the probability of experiencing these effects. 
However, some in vitro studies reported that there is a relationship between the besides 
the NSAIDs and COX adversities stomach: Some drugs shown to have direct cytotoxic 
action on cells of the gastric mucosa, may also be the reason of such effects (Siew & 
Francis, 2010).  
 Cardiovascular effects and the coxibs: Some prostaglandins and other substances 
produced by COX regulates complex interactions between platelets and the blood 
vessel walls. In this context, prostacyclin, a substance produced by COX-2, antagonizes 
the action of platelet aggregation by interacting with its receptor IP. However, platelets 
contain only one isoform of COX, able to convert a large quantity of arachidonic acid to 
a potent aggregating agent, thromboxane A2 (TXA2). Therefore, with the 
administration of selective COX-2 drugs (coxibs), an imbalance can occur in the 
production of prostacyclin and TXA2, reflecting in a prothrombotic/antithrombotic 
blood imbalance and a consequent increase in risk of thrombotic events (Topol, 2004; 
Antman et al., 2005). In this context, the studies of Grahamm and coworkers (2005) 
showed an increase of 1.49 times in the risk of acute myocardial infarction patients for 
consuming rofecoxib at a dose of 25mg/day (maximum dose chronic allowed) in a 
three years period. Additionally, the author noticed an increase of 3.58 times in this risk 
with the consumption of doses greater than 25mg/day of celecoxib. A number of other 
studies reported a significant increase in the risk of developing acute myocardial 
infarction associated with the use of such medicines (Bresalier et al., 2005). Given these 
results, the Food and Drug Administration (FDA) has formalized the limited use of 
these drugs. Two of them (rofecoxib and valdecoxib) were still withdrawn from the 
market (United States Food and Drug Administration [FDA], 2011).  
 Erectile dysfunction: Inhibition of prostaglandin synthesis and TXA2 by NSAIDs may 
interfere with the physiological process of penile erection through nitric oxide, which is 
an essential physiological signal for penile erection (Shiri et al., 2006). According to the 
study of Shiri and coworkers, 2006, Erectile dysfunction is related to the used therapy, 
regardless the incident disease. The author of the study showed that the onset of the 
erectile dysfunction in patients with arthritis treated with NSAIDs was lower than 
expected in the use of the drug in the absence of a disease, indicating a negative 
function between the use of NSAIDs in arthritis and the risk of developing the disorder. 
In addition, the study concluded that it is a reversible process, with enhanced sexual 
performance when the drug is discontinued. 
 Nephrotoxicity: Inhibition of COX-1 results in declining levels of renal vasodilatory 
prostaglandins, which among other effects, maintains renal blood flow and glomerular 
filtration rates. This effect is mainly exerted by them relaxing preglomerular resistance 
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and acting as angiotensin II and norepinephrine antagonists. Aditionally, they cause an 
increase in organ perfusion and reduction in the release of noradrenaline. In this context, 
the inhibition of such mechanisms tends to decrease the total renal perfusion and 
redistribute blood flow to the cortex, especially when there is stimulation of the renin-
angiotensin-aldosterone system and/or stimulation of the sympathetic nervous system. 
Such processes may result in acute renal vasoconstriction, medullar ischemia, and under 
certain conditions, acute renal failure. Therefore, the use of NSAIDs may result in varying 
degrees of renal dysfunction, ranging from the reversible commitment of glomerular 
filtration rate to irreversible renal damage (Winkelmayer et al. 2008; Pountos, 2011). 
2.4 Contra-indications 
The contraindications for NSAIDs are quite understandable and are closely related to its 
adverse effects. The FDA proposes the contraindications for hypertensive patients, patients 
with chronic renal, cardiovascular and gastroesophageal diseases (Keenan et al., 2011). 
Additionally, there is not a clear dividing line for the clinical use of NSAIDs and their 
toxicology, where it is necessary the cautious interpretation of clinical risk factors. Such 
factors may increase the likelihood of developing these side effects, and are described in 
Table 3 (Holdgate & Pollock, 2004; Berenbaum, 2004). 
Risk factors related to the consumption of NSAIDs 
Patient Older than 65 years, consumption of alcohol and/or smoke. 
Clinical History 
Gastrointestinal (GI) events or ulcers, prior induction of GI events by NSAIDs 
consumption, comorbid conditions, poor functional status. 
Drug Chronic use, high doses, concomitant use with other NSAIDs. 
Table 3. Risk factors related to the use of NSAIDs (Pountos et al., 2011).  
Several studies include pregnant and lactating women in the clinical contraindicated profile, 
which culminated in a warning issued by the Adverse Drug Reactions Advisory Committee 
(ADRAC) in 1991. It emphasized the congestive heart failure and poor prognosis risks 
related to the use of NSAIDs during pregnancy (Hofstadler et al., 1996), reporting cases of 
premature closure or constriction of the ductus arteriosus in women with diclofenac, 
indomethacin and mefenamic acid treatment due to low back pain, premature labor and 
polyhydramnios, respectively. 
2.5 Drug interactions 
Some studies report that the administration of traditional NSAIDs concomitantly with 
Aspirin® may antagonize its antiplatelet action, compromising its cardioprotective function 
(Kurth et al., 2003). Additionally, the combination of NSAIDs and coxibs with low-dose 
Aspirin® significantly increases the likelihood of gastroinestinais adverse events compared 
with the isolated use of any NSAID (Gladding et al., 2008). 
The combined therapy of these drugs with angiotensin-converting enzyme (ACE) inhibitors 
can cause renal failure (Seeling et al., 1990), commonly seen in elderly patients. The same 
results from the attenuation of the effectiveness of ACE inhibitors due to the blocked 
production of vasodilator and natriuretic prostaglandins by NSAIDs. The drug interaction 
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also occurs with thiazide diuretics, which can cause impaired renal function and electrolyte 
imbalance (Secoli, 2010). 
Although they are often used to treat rheumatoid arthritis and cancer, the concomitant use 
of NSAIDs and methotrexate leads to drug interaction, increasing the blood concentration 
and time of excretion of methotrexate. According to Maeda et al., 2008, there is a 
competition for the renal transporter, the main route of elimination of methotrexate.  
NSAIDs also present interactions with alcohol. Studies have demonstrated that this 
interaction causes the prolongation of the bleeding mediated by Aspirin® when 
administered concomitantly. This mechanism is not yet well understood, but some in vitro 
studies show that this relationship arises from the increase in the inhibiting power of 
prostacyclin on platelet aggregation (Jakubowski et al., 1988). 
2.6 Main categories of NSAIDs 
 Salicylates: Aspirin® is the pioneer of this class of anti-inflammatory drugs. It is often 
used for prophylaxis of cardiovascular events at a dosage of 40 to 80 mg/day. 
Additionally, it has analgesic action and antipyretic in the dosage of 325 to 650mg every 
4 to 6 hours. At a dosage of 1g every 4 to 6 hours is indicated for the treatment of 
rheumatic fever. The dosage for children is changed, being 10mg/kg every 4 to 6 hours. 
Diflunisal® (difluorophenyl) has about 4 to 5 times more analgesic and anti-
inflammatory power than Aspirin®. However, its antipyretic effect is reduced. The 
administration of diflunisal is performed at doses of 250 to 500mg every 8 to 12 hours. It 
presents fewer side effects on platelets and the gastrointestinal tract. Its excretion can be 
achieved through breast milk, being contraindicated for pregnant women. 
 Para-aminophenol derivatives: Acetaminophen or Paracetamol has effective analgesic 
and antipyretic activity, but its anti-inflammatory activity is insufficient. It is used at a 
dosage of 10 to 15 mg/kg every 4 hours, not exceeding the maximum of 5 doses every 
24 hours. High doses of acetaminophen cause the production of toxic metabolites and 
hepatic necrosis. 
 Acetic acid derivatives: Indomethacin is 10 to 40 times more potent than salicylic acid. 
Its peak blood concentration is reached 1-2 hours after administration. It is used at a 
dosage of 25 mg 2-3 times/day or 75 to 100 mg/night. Its side effects affect 30 to 50% of 
users, characterized by frontal headache, neutropenia and thrombocytopenia. About 
20% of patients discontinue the therapy. Fenamates have similar effectiveness 
compared to acetylsalicylic acid, but isolated cases of hemolytic anemia have been 
reported. Its side effects can reach about 25% of users. Tolmetin, a heteroaryl acetate 
derivative, also has similar effectiveness compared to Aspirin®. It is used at a dose of 
400 to 600mg, three times a day, and 20mg/kg/day for children, in 3 to 4 fractionated 
doses. The absorption of Tolmetin is delayed and decreased in the presence of food. The 
interruption of therapy occurs in 5-10% of patients. Diclofenac, a phenylacetate 
derivative, is administered in doses of 50mg three times daily or 75mg, 2 times a day. It 
is more potent than Aspirin®, but 20% of patients develop side effects, 2% discontinue 
the use and 15% develop elevation of liver enzymes. 
 Propionic acid derivates: In general, they are better tolerated than Aspirin®, with 
equivalent to or higher power than the same. Ibuprofen is widely used in clinical 
practice, and presents a large potential to cause renal toxicity. About 10 to 15% of users 
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discontinue treatment due to adverse effects. It is administered at a dose of 200 to 
400mg every 4 to 6 hours for analgesia, whereas for anti-inflammatory the dosage is 
300mg every 6-8h or 400 to 800mg three to four times a day. The dosage for anti-
inflammatory for children decreases to 5 to 10mg/kg every 6h, with the maximum dose 
of 40 mg/kg/day. In children, anti-inflammatory action is achieved with dosages of 20 
to 40 mg/kg/day in 3 to 4 fractionated doses. Naproxen has a long half-life of 14 hours, 
and can provide cardioprotection in some patients. It is used in the maximum daily 
dose of 1000 mg being 250 mg 4 times daily or 500 mg two times a day. For children, 
anti-inflammatory dosage is reduced to 5mg/kg, two times a day. In elderly patients, 
the drug has lower protein binding and delayed excretion, increasing the likelihood of 
toxicity in these patients. In the case of fenoprofen, the dosage is 200mg 4-6 times a day. 
About 15% of users experience side effects, but few discontinue use. Drugs with high 
half-life, as oxaprozin (40 to 60h) allows administration once daily. However, it is 
indicated for fever or acute analgesia because the onset of action is slow. Oxaprozin is 
used in dosage from 600 to 1800 mg/day. 
 Enolic acid derivates: This class is constituted by piroxicam, meloxicam and 
nabumetone. Both meloxicam and nabumetone have relative selectivity for COX-2. 
Piroxicam has equivalent power to Aspirin® and is better tolerated. However, it can 
inhibit the activation of neutrophils and the activity of collagenase and proteoglycanase. 
This drug is administered in daily doses of 20mg. About 20% of users develop side 
effects, while 5% discontinue the treatment. Nabumetone has fewer side effects than 
many NSAIDs. Its administration is performed at doses of 500 to 1000mg, 1 to 2 times a 
day. Meloxicam dosage is 7.5 to 15 mg/day (Goodman et al., 2010). 
3. Glucocorticosteroids (GCs) 
Glucocorticosteroids (GCs) (glucocorticoids; also known as corticosteroids or steroids) are 
steroid hormones derived from cholesterol metabolism. Their basic molecular structure is 
the cyclopentanoperhydrophenanthrene, derived from cholesterol.  
The natural GC representative is the cortisol or hydrocortisone. They are effective anti-
inflammatory and immunosuppressive agents, produced naturally in the adrenal gland 
after stimulation of the hypothalamic-pituitary-adrenal (HPA) (Fernandes et al., 2008; 
Barnes & Adcock, 2009). Since the availability of cortisone in the late 1950s, several synthetic 
GC agonists have been developed, such as prednisone, dexamethasone and betamethasone 
(Löwenberg et al., 2008). The synthetic GCs are obtained from folic acid (taken from cattle) 
or some plants of the families Liliaceae and Dioscoreaceae (Timóteo & Dos Santos, 2008). For 
decades, they have been among the most commonly prescribed classes of 
immunomodulatory and anti-inflammatory drugs, being widely used as treatment of choice 
for several autoimmune and inflammatory diseases, including asthma, rheumatoid arthritis, 
inflammatory bowel disease and polymyalgia rheumatica. However, serious side effects, 
such as osteoporosis, skin atrophy, cushingoid appearance, diabetes and glaucoma, 
frequently accompany GC therapy, which place limitations on the use of higher dosages and 
long-term use of GCs (Flammer & Rogatsky, 2008; Löwenberg et al., 2008). Moreover, 
nowadays, various side effects of glucocorticoids are well-known and physicians often 
anticipate on these side effects (De Nijs, 2008). 
www.intechopen.com
 
State of the Art of Anti-Inflammatory Drugs 
 
127 
3.1 Molecular actions of glucocorticosteroids 
GCs act through many molecular mechanisms. One of them occurs through traditional 
glucocorticoid receptor mediated pathways to directly regulate gene expression. In this 
mechanism, the CGs freely diffuses across the cell membrane and act by binding to and 
activating specific cytosolic glucocorticoid receptors (GR). In its inactive state, the GR exists 
as a cytosolic protein bound to two heat shock protein 90 chaperonin molecules. The 
binding to the GC ligand results in a conformational change that allows dissociation of the 
GR from the protein complex, and a quick translocation into the cell nucleus where they can 
modulate gene transcription either by stimulation or inhibition (De Paiva & Pflugfelder, 
2008; Barnes & Adcock, 2009). The glucocorticoid-receptor complex can either induce key 
anti-inflammatory genes that encode anti-inflammatory molecules (e.g. lipocortin-1, IL-10, 
IL-1Rǂ6, TGF-ǃ and inhibitory IkB proteins) following direct association with glucocorticoid 
response elements (GREs) in the promoter regions of these genes, or selectively repress 
specific inflammatory genes that encode cytokines (e.g. IL-1, IL-6, IL-8, TNF-ǂ), chemokines, 
adhesion molecules (e.g. adhesion molecules E-selectin, ICAM-1, VCAM-1), inflammation-
associated enzymes (e.g. phospholipase A2, COX-2, iNOS), lipid mediators of inflammation 
(e.g. prostaglandins) and receptors by protein-to-protein interaction with transcription 
factors such as the nuclear factor (NF)-кB and activator protein 1 (AP-1), which interact with 
transcriptional coactivator molecules to activate gene transcription (Derendorf & Meltzer, 
2008; Fernandes et al., 2008). Multiple mechanisms are involved in GC-mediated anti-
inflammatory activity in addition to direct GR/NF-кB interaction, such as GC-induced up-
regulation of IкB and glucocorticoid-induced leucine zipper (GILZ), two proteins able to 
bind and inhibit NF-кB activation (Cuzzocrea et al., 2008). 
Furthermore, it has been reported that peroxisome proliferator activated receptor-ǂ (PPAR-
ǂ) can contribute to the anti-inflammatory activity of GCs. PPAR-ǂ is an intracellular 
transcription factor activated by fatty acids that plays a role in inflammation. Previous 
studies indicate that PPAR-ǂ expression is induced by GCs and can mediate some of the GC 
effects, such as modulation of insulin sensitivity and resistance, and can contribute to GC-
induced hyperglycemia and blood pressure increase. Moreover, it has been reported that 
PPAR-ǂ activation can result in inhibition of NF-кB activation and inflammatory gene 
expression (Cuzzocrea et al., 2008).  
3.2 Therapeutic uses 
 Skin diseases: Several skin diseases are typically treated with systemic or topical GCs. 
The main indications are psoriasis, contact dermatitis, atopic dermatitis, exfoliative 
erythroderma, pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, 
cicatricial pemphigoid, gestational herpes, acquired epidermolysis bullosa, linear IgA 
bullous dermatosis, Stevens Johnson syndrome, toxic epidermal necrolysis, erythema 
multiforme minor, lupus erythematosus, dermatomyositis, vasculitis, pyoderma 
gangrenosum, sweet's syndrome, behcet's disease, lichen planus, sarcoidosis and 
chronic urticaria (Pereira et al., 2007; Akama et al., 2009). In pediatric dermatology, 
long-term systemic steroids may be used for the treatment of erythroderma due to 
atopic eczema, pustular psoriasis, childhood pemphigus, chronic bullous dermatosis of 
childhood, systemic lupus erythematosus, pyoderma gangrenosum or complicated 
hemangiomas (Deshmukh, 2007). 
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 Respiratory tract diseases: Intranasal GCs are effective treatments for allergic rhinitis, 
rhinosinusitis, and nasal polyposis. They are the most common treatment for patients 
with nasal polyposis and have been designated as the treatment of choice for allergic 
rhinitis (Derendorf & Meltzer, 2008; Zele et al., 2010). The systemic GCs are effective in 
treating allergic rhinitis, but the high risk of serious toxicity with long-term 
administration has hindered their usefulness. The first successful use of GC as a 
pressurized aerosol with no apparent evidence of systemic toxicity was the 
beclomethasone in 1972. In the following years, corticosteroid molecules have been 
refined to create more potent agents with lower bioavailability and enhanced safety 
profiles. Nowadays, various compounds are approved for the management of allergic 
rhinitis in the United States: triamcinolone acetonide, flunisolide, budesonide, 
beclomethasone dipropionate, ciclesonide, fluticasone propionate, mometasone furoate, 
fluticasone furoate (Derendorf & Meltzer, 2008; Zele et al., 2010). Likewise, GCs are the 
most effective and widely used anti-inflammatory drugs for the treatment of asthma 
(Maneechotesuwan et al., 2010; Hagan et al., 2011). The introduction of GCs, in the form 
of cortisone, for the treatment of asthma more than 60 years ago resulted in pronounced 
clinical effects. Today, inhaled GCs are considered to be the most effective anti-
inflammatory treatment, safe in appropriate doses when given to asthmatic children 
and adults who need regular therapy to control symptoms or prevent exacerbations 
owing to reduced systemic absorption and risk of systemic side-effects (Rottier & 
Duiverman, 2009). Moreover, about 40-50% of patients with chronic obstructive 
pulmonary disease are being treated with inhaled GCs (Löwenberg et al., 2008).  
 Rheumatologic diseases: Long-term therapy with GCs is often necessary to control the 
symptoms of rheumatoid arthritis and other rheumatic conditions (Neeck et al., 2002; 
Paul-Clark et al., 2002). It has been reported that up to 60% of patients with rheumatoid 
arthritis are treated more or less continuously with GCs (Löwenberg et al., 2008). 
Polymyalgia rheumatica is also a common indication for long-term glucocorticoid 
therapy and has a favorable prognosis. However there is considerable heterogeneity in 
patients’ clinical course and response to this therapy. In addition, the patients are 
usually maintained on the lowest possible dose to control disease symptoms and to 
minimize GCs complications (Salvarani et al., 2002; Kremers et al., 2007). 
 Gastrointestinal inflammatory diseases: Glucocorticoids are an effective treatment for 
inflammatory bowel disease such as ulcerative colitis and Crohn's disease (Löwenberg 
et al., 2008). Crohn's disease is a chronic inflammatory disorder of the bowel whose 
cause is unknown. During the acute phase of the disease, glucocorticoids such as 
prednisolone and prednisone are commonly used (Thomsem et al., 1998). In ulcerative 
colitis prednisolone was found to induce remission of symptoms concomitantly with 
reduction of endoscopically viewed colonic inflammation (Olaison et al., 1990). 
However, failure to respond, acutely or chronically, to GC therapy is a common 
indication for surgery in inflammatory bowel disease, with as many as 20% of patients 
with ulcerative colitis and approximately 50% of patients with Crohn’s disease 
requiring surgery in their lifetime as a result of poor response to medical therapy 
(Farrell & Kelleher, 2003). 
 Other therapeutic uses: GCs have been successfully used in the management of 
patients with renal diseases, allergic reactions, thrombocytopenia, corneal epithelial 
disease in dry eye and Graves' ophthalmopathy (De Paiva & Pflugfelder, 2008). In 
addition, these agents play an important role in the treatment of immune disorders, 
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including reducing the immune response in autoimmune diseases and organ 
transplantation (Grbović; Radenković, 2005). In short term, high dose suppressive GC 
therapy is also indicated in the treatment of medical emergencies such as necrotising 
vasculitis, status asthmaticus and anaphylactic shock (Swartz; Dluhy, 1978).  
3.3 Side effects and contraindications 
The physiologic effects of GCs are numerous and widespread. They influence electrolyte 
and water balance, carbohydrate metabolism, protein metabolism, lipid metabolism, 
cardiovascular system, skeletal muscle, central nervous system (CNS), formed elements of 
blood and affect other organs and tissues in a wide variety of ways (Chaney, 2002). The 
effect on fluid and electrolytes is due to their mineralocorticoid effect. It causes salt and 
water retention leading to edema, weight gain and hypertension. The potassium loss 
leading to hypokalemia can cause severe weakness (Deshmukh, 2007). Hyperglycemia is a 
known complication of GC therapy caused mainly by increased hepatic capacity for 
gluconeogenesis and reduced sensitivity to insulin. This increase in blood sugar levels can 
be a negative prognostic factor for ill patients (Davenport et al., 2010). Furthermore, GCs 
also increase lipid levels because of increased lipid production in liver and due to lipolysis 
from adipose tissue; and cause redistribution of carbohydrate, fat and protein reserves. This 
along with the increase in appetite can lead to the Cushingoid habitus (moon facies, buffalo 
hump and central obesity) (Deshmukh, 2007).  
Due to these effects in the body, GC therapy is frequently hampered by severe side effects, 
especially when used in high doses for prolonged durations. The adverse effects of 
corticosteroids seen during short-term therapy include increased appetite, weight gain, fluid 
retention, gastritis, headache, mood swings, increase in blood sugar, hypertension and 
glaucoma. Adverse effects seen when therapy is given for longer duration include suppressed 
immunity, increased susceptibility to infections, increased cholesterol levels, weight gain, 
osteoporosis, deposition of body fat, thinning of skin, cataracts, stunting and 
hypothalamopituitary axis suppression (Löwenberg et al., 2008). Bone loss is one of the most 
important side effects of GC use. It starts promptly after initiation and mainly takes place in 
the first six months of treatment. Several studies and reports show a decrease in bone mineral 
density and an increased risk of fractures during GC use. The main effect of GC on bone is 
inhibition of osteoblast function, leading to a decrease in bone formation (De Nijs, 2008). 
These side effects are responsible for several contraindications and limit the use of higher 
dosages and long-term use of GCs (Niedner, 2001; Löwenberg et al., 2008) The most 
important contraindications for the therapy of systemic GCs are uncontrolled hypertension, 
glaucoma, uncontrolled diabetes mellitus, osteoporosis, acute viral infections, bacterial 
infections, systemic fungal infections, parasitic diseases and psychiatric history (Niedner, 
2001). Thus, the clinician must carefully consider in each case the presence of 
contraindications and the gains that can reasonably be expected from GC therapy versus the 
inevitable undesirable side effects of prolonged therapy (Niedner, 2001). The risk of 
glucocorticoid-induced osteoporosis can be reduced, for example, by general measurements 
like prescribing GCs in a low dose and for a short period of time. Furthermore, calcium and 
plain vitamin D3 supplementation and pharmacological intervention with bisphosphonates 
are considered as important support for prevention and treatment of glucocorticoid-induced 
osteoporosis (De Nijs, 2008). 
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3.4 Glucocorticosteroid resistance in inflammatory diseases 
GCs resistance or insensitivity is a major barrier to the treatment of several common 
inflammatory diseases, including chronic obstructive pulmonary disease and acute 
respiratory distress syndrome; it is also an issue for some patients with asthma, rheumatoid 
arthritis, and inflammatory bowel disease. The resistance to the anti-inflammatory effects of 
GCs can be induced by several mechanisms that may differ between patients. These 
mechanisms include reduced GR expression, altered affinity of the ligand for GR, reduced 
ability of the GR to bind to DNA, increased expression of inflammatory transcription factors 
(eg, NF-кB, AP-1), raised macrophage migration inhibitory factor, and increased P-
glycoprotein-mediated drug efflux. Patients with GC resistance can be treated with 
alternative broad-spectrum anti-inflammatory treatments, such as calcineurin inhibitors and 
other immunomodulators, or novel anti-inflammatory treatments, such as inhibitors of 
phosphodiesterase 4 or NF-кB (Barnes & Adcock, 2009). 
3.5 Main glucocorticoid drugs 
Several synthetic GC agonists have been developed since the availability of cortisone in the 
late 1950s (Löwenberg et al., 2008). The pharmacologic differences among various GCs 
derivatives result from structural alterations of the basic steroid nucleus and its side groups 
(Cevc & Blume, 2004). The main representatives of this class drugs and their peculiarities are 
described below. 
 Hydrocortisone: A steroid hormone secreted by the adrenal cortex, is a short-acting GC 
(biological half-life of 8–12 hours) available in drug forms as unchanged hormone either 
different salts thereof (acetate, cypionate, sodium phosphate, butyrate, valerate, and 
sodium succinate). The hydrocortisone is used orally, in combination with 
fludrocortisone, for replacement therapy in adrenal insufficiency (Deshmukh, 2007). 
The effect of this agent on the milk is not known (Damiani et al., 2001). Hydrocortisone 
sodium succinate, the water-soluble derivative, is administered parenterally for a 
quicker effect in emergencies (Deshmukh, 2007); 
 Prednisone: An intermediate-acting GC (biological half-life of 12–36 hours), is four to 
five times more potent than hydrocortisone (Zoorob; Cender, 2000). This GC is a 
prodrug, converted in normal circumstances in the body to prednisolone. It’s widely 
used orally in the acute and long-term management of various disorders and for anti-
inflammatory and immunosuppressant effects (Deshmukh, 2007). The use of 
prednisone can be done in nursing mothers (Damiani et al., 2001); 
 Methylprednisolone: An intermediate-acting GC, is four to five times more potent than 
hydrocortisone as well as prednisone (Zoorob; Cender, 2000). It has less 
mineralocorticoid activity than prednisone/prednisolone while having a similar 
duration of action and may be preferred when mineralocorticoid effect is particularly 
undesirable. An alternate day regimen should be considered during long-term therapy 
(Deshmukh, 2007). The use of methylprednisolone can be done in nursing mothers, 
only in low dose (less than 8 mg/day) and the child should be breastfed after 4 hours of 
taking the GC (Damiani et al., 2001);  
 Triamcinolone: An intermediate-acting GC, five times more potent than hydrocortisone 
can be done in nursing mothers (Damiani et al., 2001); 
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 Dexamethasone: Is a long-acting GC (biological half-life of 36–72 hours) highly potent, 
available as oral, parenteral, topical (spray), and ophthalmic dosage forms (Cevc; 
Blume, 2004). Its potency is about 25 times greater than the short-acting products 
(Zoorob; Cender, 2000). This GC has minimal mineralocorticoid activity and is used 
most often in the management of acute disorders because prolonged treatment is 
associated with severe suppression of the HPA axis. Furthermore it's not suitable for 
alternate day regimens where the aim is to maintain the responsiveness of the HPA axis 
(Deshmukh, 2007); 
 Betamethasone: Similar to dexamethasone, is unsuitable for long-term alternate-day 
therapy due to its long duration of action (Deshmukh, 2007). 
The therapeutic dosing regimen of these agents is very wide and depends on the indication 
for treatment. The basis for the use of different dosages in different clinical conditions is 
essentially empirical. Thus, the appropriate dose for a specific therapeutic effect should be 
determined by trial and error as well as should be reassessed periodically, particularly when 
complications arise during a therapy (Buttgereit et al., 2002) 
3.6 Drug Interactions 
GCs are known substrates and inducers of cytochrome P450 3A (CYP3A), enzymes which 
constitute the major phase one drug-metabolizing enzyme family in humans (Anglicheau et 
al., 2003). Thus, drugs that inhibit CYP 3A4, such as erythromycin, clarithromycin, 
ketoconazole, itraconazole, act to reduce serum levels of GC, consequently increasing the 
incidence and severity of side effects of GCs. On the other hand, drugs that induce CYP 3A4, 
such as barbiturates, phenytoin, rifampin, act to reduce serum levels, consequently 
decreasing the activity of several systemic GCs (Pereira et al., 2007).  
These agents are also known substrates and inducers of P-glycoprotein (P-gp), product of 
the multidrugresistance gene responsible for the transmembrane efflux of many drugs. P-gp 
reduces the intracellular concentration of various xenobiotics. The high dose steroid therapy 
was recently shown to lower tacrolimus blood levels in the rat, as a result of the induction of 
P-gp and CYP3A in the intestine and liver (Anglicheau et al., 2003). 
Other drug interactions, which involve other mechanisms, are described below (Table 4): 
Drug Mechanism of drug interaction Consequence 
Estrogens ↑ half-life and ↓ clearance of GCs ↑ action of GCs 
Antacids ↓ absorption of GCs ↓ action of GCs 
Cholestyramine ↓ absorption of GCs ↓ action of GCs 
Ephedrine 
↓ half-life and increased clearance of GCs, 
particularly of dexamethasone 
↓ action of GCs 
Cyclosporine 
Inhibition of metabolism of cyclosporine by 
prednisolone 
↑ action of cyclosporine 
Isoniazid ↓ level serum of isoniazid by GCs ↓ action of isoniazid 
Salicylates ↑ clearance of salicylates by GCs ↓ action of salicylates 
Digitalics 
GC-induced hypokalemia may ↑ serum 
concentration of digitalics 
↑ action of 
digitalics 
Table 4. GC interactions and clinical consequences (Pereira et al., 2007; Anti et al., 2008) 
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4. New anti-inflammatory agents 
Nowadays, the increasing research developments in the fields of chemistry, pharmacology 
and molecular modeling, among others, share a common purpose: the pursuit and design of 
new agents and therapeutic targets. In this context, one area has raised interest in the field of 
therapeutic innovation: the treatment of inflammatory diseases. 
Although its high therapeutic power, the anti-inflammatory therapies on the market have a 
high incidence of side effects resulting from its use (especially chronic), making unfavorable 
the risk/benefit ratio of these medications in many patients. Given this context, it becomes 
necessary to introduce new therapeutic options with more effective, specific and with fewer 
adverse effects actives. Currently, several targets and agents are being tested for their anti-
inflammatory activity, such as: 
 Components of signal transduction (e.g. NF-ĸB and mitogen-activated protein kinase 
such as p38 kinase and c-Jun N-terminal kinases - JNKs): Some of small molecules that 
inhibit p38 kinase are in the final stages of clinical trials (Kulkarni et al., 2006);  
 Dual inhibitiors of COX-2 and 5-lipoxygenase (5-LOX): Various structural families of 
dual inhibitors have been designed and several compounds are currently undergoing 
pre-clinical or clinical development. By preventing the biosynthesis of both prostanoids 
and LTs, they are potent anti-inflammatory agents (Charlier & Michaux, 2003);  
 Proinflammatory cytokines: Given their central role in the regulation of inflammatory 
responses, cytokines are clearly appealing targets for therapeutic intervention. 
Emphasis has been placed on cytokines that are produced early in the inflammatory 
cascade such as TNF-ǂ and IL-6. Therapeutics neutralizing these cytokines or their 
receptors are already on the market or in late-phase development (Kopf et al., 2010). 
Recently, a new biological target for anti-inflammatory therapy has been identified: the 
peroxisome proliferator-activated receptors (PPAR). PPARs are ligand-activated transcription 
factors belonging to the nuclear receptor superfamily. This superfamily includes steroidal 
transcription factors, non-steroidal receptors, PPARs and liver X receptor (LXR). 
Three major subtypes of the receptor have been identified: PPAR-ǂ, PPAR-ǃ and PPAR-Ǆ. 
Originally, the PPAR activity was thought to be limited to lipid metabolism and glucose 
homeostasis, being the PPAR-Ǆ agonists (known as thiazolidinediones) commonly 
prescribed for the treatment of diabetes. Later studies showed that PPAR activation 
regulates other biological functions such as cell proliferation, differentiation and apoptosis 
(Moraes et al, 2006).  
Several studies have showed that PPAR-ǂ and PPAR-Ǆ inhibit the expression of 
inflammatory genes. All available data indicate that the activation of PPAR-ǂ and PPAR-Ǆ 
modulates oxidative stress-sensitive pathways, NF-ĸB, AP-1, and signal transducers and 
activators of transcription (STAT). These findings strongly indicate the potential as 
therapeutic target sites of PPAR-ǂ and PPAR-Ǆ in controlling the inflammatory process and 
age-related inflammatory diseases. In support of evidence on the role of PPAR-ǂ in the 
suppression of NF-B activity, PPAR-ǂ agonists are shown to decrease production of pro-
inflammatory mediators such as IL-6, IL-12, IL-1a, iNOS, and COX-2, which are associated 
with the decrease in NF-B activation. 
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Apart from its role as a transcription factor, PPAR-Ǆ also acts as a trans-repressor of 
macrophage inflammatory genes. Ligand-independent activation of PPAR-/ can suppress 
bowel disease by down regulation of inflammatory signaling (Chung et al., 2008). 
During inflammatory responses, PPARs can be activated by eicosanoids. Ligands for PPAR-
Ǆ include leukotriene B4, 8(S)-hydroxyecosatetraenoic acid (HETE), 15-deoxy-D-12,14-
prostaglandin J2, 15-HETE and 13-hydroxyoctadecadienoic acid. Nuclear receptors can 
regulate macrophage gene expression in response to changes in cellular lipids and 
arachidonic acid metabolites that occur during inflammatory responses (Rizzo & Fiorucci, 
2006). 
PPAR-Ǆ protein was identified in the antigen presenting cells, monocytes and macrophages 
and synthetic PPAR-Ǆ agonists including pioglitazone, troglitazone and rosiglitazone were 
shown to suppress production of inflammatory cytokines by these cells (Jiang et al., 1998; 
Ricote et al., 1998). Subsequently, PPAR-Ǆ was identified in dendritic cells. The same 
thiazolidinedione compounds were demonstrated to decrease dendritic cell secretion of IL-
12, a potent TH1-type inflammatory cytokine (Martin, 2010). 
In this context, PPAR-Ǆ agonists have been investigated for their anti-inflammatory effects. 
Beneficial effects of the PPAR-Ǆ activator, rosiglitazone, were reported in two recent clinical 
trials for the treatment of Ulcerative Colitis (Lewis et al., 2008; Liang & Ouyang, 2008). 
Animal models of inflammation are now being used to explore the utility of PPAR-Ǆ 
agonists in other inflammatory diseases. 
5. Conclusion 
The steroidal and non-steroidal anti-inflammatory drugs provide efficient therapies for the 
treatment of inflammatory diseases. However, several adverse effects related to acute and 
especially cronic use of such drugs limit its use in some patients. Thus, the clinician should 
take into account the risks and benefits of treatment for the patient before starting the 
therapy. 
Recent searches for new targets and anti-inflammatory agents aim to attend the demand for 
new secure and equally efficient therapies for the treatment of inflammation. In this context, 
PPAR- agonists appear as candidates for anti-inflammatory drugs. 
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